Drug Trial Radar · NCT03439280
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Apr 20, 2018
Primary completion
Jan 28, 2022
Study completion Jan 28, 2022
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.
Conditions
- Relapsed/Refractory
- Multiple Myeloma
Interventions
MezagitamabDrug
Mezagitamab subcutaneously.
PomalidomideDrug
Pomalidomide orally.
DexamethasoneDrug
Dexamethasone orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
- Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (cycle length=28 days)
- Phase 1: Number of Participants With Grade 3 or Higher TEAEsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
- Phase 1: Number of Participants With Serious TEAEsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
- Phase 1: Number of Participants With TEAEs Leading to Treatment DiscontinuationTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
- Phase 1: Number of Participants With TEAEs Leading to Dose ModificationsTime frame: From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
- Phase 2a: Overall Response Rate (ORR)Time frame: Up to approximately 3.7 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
City of Hope - Duarte
Duarte, California
Washington University School of Medicine
St Louis, Missouri
Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center
New York, New York
Weill Cornell Medical Center, Div. of Hematology Medical Oncology
New York, New York
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon
The University of Texas MD Anderson Cancer Center
Houston, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.